The GPR40 Full Agonist SCO-267 Improves Liver Parameters in a Mouse Model of Nonalcoholic Fatty Liver Disease without Affecting Glucose or Body Weight

Mitsugi Ookawara; Keisuke Matsuda; Masanori Watanabe; Yusuke Moritoh

doi:10.1124/jpet.120.000046

Research ArticleGastrointestinal, Hepatic, Pulmonary, and Renal

Open Access

The GPR40 Full Agonist SCO-267 Improves Liver Parameters in a Mouse Model of Nonalcoholic Fatty Liver Disease without Affecting Glucose or Body Weight

Mitsugi Ookawara, Keisuke Matsuda, Masanori Watanabe and Yusuke Moritoh

Journal of Pharmacology and Experimental Therapeutics October 2020, 375 (1) 21-27; DOI: https://doi.org/10.1124/jpet.120.000046

Mitsugi Ookawara

SCOHIA PHARMA, Inc., Kanagawa, Japan

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Keisuke Matsuda

SCOHIA PHARMA, Inc., Kanagawa, Japan

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Masanori Watanabe

SCOHIA PHARMA, Inc., Kanagawa, Japan

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Yusuke Moritoh

SCOHIA PHARMA, Inc., Kanagawa, Japan

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
ORCID record for Yusuke Moritoh

Article
Figures & Data
Info & Metrics
eLetters
PDF + SI
PDF

Submit a Response to This Article

Compose eLetter

Title *

Contents

More information about text formats

Plain text

No HTML tags allowed.
Web page addresses and e-mail addresses turn into links automatically.
Lines and paragraphs break automatically.

Author Information

Contributors
First Name and Middle Initial * First or given name, e.g. 'Peter'. Last Name * Your last, or family, name, e.g. 'MacMoody'. Email Address * Your email address, e.g. higgs-boson@gmail.com Occupation * Your role and/or occupation, e.g. 'Orthopedic Surgeon'. Affiliation * Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.

Statement of Competing Interests

Competing interests? *

Yes

Please describe the competing interests

Vertical Tabs

Jump to comment:

No eLetters have been published for this article.

PreviousNext

In this issue

Journal of Pharmacology and Experimental Therapeutics

Vol. 375, Issue 1

1 Oct 2020

Table of Contents
Table of Contents (PDF)
About the Cover
Index by author
Editorial Board (PDF)
Front Matter (PDF)

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following The GPR40 Full Agonist SCO-267 Improves Liver Parameters in a Mouse Model of Nonalcoholic Fatty Liver Disease without Affecting Glucose or Body Weight

Message Subject (Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics

Message Body (Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.

Your Personal Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Citation Tools

Research ArticleGastrointestinal, Hepatic, Pulmonary, and Renal